Medical CBRN Defense Consortium (MCDC)
The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.
Technology Focus Areas3
major offering areas as: Liver Disease Treatments, Immune
Modulating Therapies, Next Generation Peptide Therapeutics,
Conjugated Immunostimulants, Intranasal Covid-19 Vaccine, and I...
of ARAI rescue Auto-Injector.
as: Custom organic synthesis of novel compounds, High-throughput
screening, Synthesis of analogs of lead compounds, Chemical
synthesis process development and optimization, Formulation dev...
Synthesis and Baculovirus (BEV) Recombinant Protein Expression.
Recombinant Protein includes: Acetylcholinesterase (AChE),
Paraoxonase (PON 1), Indoleamine 2,3-Dioxygenase (IDO1), HMGA1...
Biomedical, Drug, and Small Molecule Therapeutics Research and
Development Infectious Diseases.